Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Armata Pharmaceuticals, Inc. (ARMP)

2.97   0.3 (11.24%) 09-27 11:02
Open: 2.74 Pre. Close: 2.67
High: 3.169 Low: 2.74
Volume: 18,934 Market Cap: 107(M)

Technical analysis

as of: 2023-09-27 10:45:14 AM
Short-term rate:       
Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected.
Mid-term rate:       
Target: Six months: 3.79     One year: 4.3
Support: Support1: 2.52    Support2: 2.1
Resistance: Resistance1: 3.24    Resistance2: 3.69
Pivot: 2.83
Moving Average: MA(5): 2.72     MA(20): 2.95
MA(100): 2.17     MA(250): 2.29
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 25.1     %D(3): 16.7
RSI: RSI(14): 51.8
52-week: High: 5.26  Low: 0.82
Average Vol(K): 3-Month: 186 (K)  10-Days: 27 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ARMP ] has closed below upper band by 25.9%. Bollinger Bands are 45.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.73 - 2.75 2.75 - 2.76
Low: 2.61 - 2.63 2.63 - 2.65
Close: 2.64 - 2.67 2.67 - 2.7

Company Description

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Headline News

Tue, 26 Sep 2023
Armata Pharmaceuticals Announces First Patient Dosed in the ... - PR Newswire

Thu, 21 Sep 2023
Armata Pharmaceuticals to Participate in the Cantor Global ... - PR Newswire

Tue, 22 Aug 2023
Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why - Zacks Investment Research

Mon, 14 Aug 2023
Armata Pharmaceuticals Announces Second Quarter 2023 Results ... - BioSpace

Mon, 24 Jul 2023
Armata, Janux top healthcare gainers; Kodiak, BioCardia lead losers ... - Seeking Alpha

Tue, 11 Jul 2023
Armata Pharmaceuticals Announces New Financing and ... - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 0 (M)
% Held by Insiders 0 (%)
% Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) 0
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.